In March 2026, a 9-year-old girl in Youngstown, Ohio, developed a persistent cough. For weeks, her mother assumed it was a stubborn cold, then a bout of bronchitis. But when the child began losing weight and running a low-grade fever that spiked at night, she took her to the community health center. The initial diagnosis was community-acquired pneumonia. Two courses of amoxicillin did nothing. A chest X-ray showed a cavity in the left upper lobe. Sputum culture confirmed Mycobacterium tuberculosis.

A 9-Year-Old's Cough That Wouldn't Quit

The girl, whose name has been withheld for privacy, had no known exposure to anyone with active tuberculosis. She lived with her mother and younger brother in a rented house on the south side of Youngstown, a city of roughly 60,000 that has seen its public health infrastructure shrink along with its industrial base. The family had no recent travel outside Ohio. The school nurse reported that the child had missed 18 days of school since January, mostly for illness. Teachers had noticed her fatigue and lack of appetite.

The local health department began a contact investigation, but it moved slowly. The index case—the girl herself—was the only confirmed infection in her household. But her mother and brother tested negative on interferon-gamma release assays. The question became: where did the strain come from? The girl's isolate was sent to the CDC's Division of Tuberculosis Elimination for genotyping. The results came back as a Beijing lineage strain, known globally for its propensity to develop multidrug resistance.

The strain was a near-perfect match to a cluster identified in Pittsburgh, Pennsylvania, in 2024. That outbreak involved seven cases, two of which were resistant to rifampin and isoniazid—the two most potent first-line TB drugs. The Youngstown case was also resistant to those drugs, meaning the girl would need a longer, more toxic regimen. It was a finding that raised alarms far beyond one family's kitchen table.

Genomic Sequencing Traces a Familiar Foe

The Beijing lineage is one of the most successful families of M. tuberculosis on the planet. It emerged in East Asia decades ago and has spread globally, often acquiring resistance mutations along the way. Whole-genome sequencing of the Youngstown isolate showed it belonged to a sublineage that had been circulating in the northeastern United States since at least 2022. The Pittsburgh cluster was the first sign of community transmission in that region. Now, Youngstown appeared to be a second node.

The CDC's molecular epidemiologists estimated that the strains diverged from a common ancestor roughly 18 months before the girl's diagnosis, suggesting the bacteria had been spreading silently. Contact tracing in Youngstown reached only about 60 percent of the girl's close contacts—classmates, neighbors, extended family. The health department said staffing shortages delayed interviews by two weeks, during which time some contacts could have been exposed and moved on.

The case underscores the value of genomic surveillance, but also its limits. The US has no national real-time TB sequencing network. The CDC runs a program called TB Genotyping Information Management System, but it relies on states to submit isolates voluntarily, and funding for the program has been flat for years. As of late 2024, roughly half of US states routinely submit isolates for sequencing. Ohio is one of them, which is why the link to Pittsburgh was caught.

The Steady Erosion of TB Control in the US

Tuberculosis in the United States is often thought of as a disease of the past, but it never really went away. The national incidence rate has plateaued at roughly 2.5 cases per 100,000 people—about 8,000 cases annually. That's low by global standards, but the rate of decline has stalled since 2020. Meanwhile, funding for local health departments has been cut by roughly 15 percent in real terms since 2020, according to the National Association of County and City Health Officials. That translates into fewer nurses, fewer disease investigators, and less capacity to do the painstaking work of contact tracing and directly observed therapy.

Treatment completion rates for active TB have fallen below 90 percent in some counties, according to CDC data. For drug-resistant TB, the rates are lower still, because the regimens are longer and harder to tolerate. The Youngstown case is not an isolated warning. In 2025, a middle school in Hartford, Connecticut, experienced a cluster of six TB cases, three of which were resistant to at least one first-line drug. The investigation there took nine months to complete and cost the state health department an estimated $1.2 million. Similarly, in 2024, a community outbreak in San Diego County involved 12 cases of multidrug-resistant TB linked to a single index patient; contact tracing reached only 70 percent of contacts, and two secondary cases emerged before the investigation concluded.

The erosion is not just a funding problem. It is also a training problem. Many young doctors and nurses have never seen a case of TB. The disease is rare enough that clinical suspicion is low. The girl in Youngstown was treated for pneumonia twice before anyone thought to test for TB. A survey of pediatricians published in 2024 found that fewer than half knew the recommended dosing for isoniazid in children. The knowledge gaps are real, and they compound the structural ones.

A Six-Month Regimen Pushes a Family to the Brink

For the girl and her mother, the diagnosis set off a cascade of logistical and financial challenges. The girl's strain was resistant to rifampin and isoniazid, so she could not take the standard six-month regimen. Instead, she was started on a regimen of bedaquiline, linezolid, and moxifloxacin—drugs that are effective but come with significant side effects. Bedaquiline can cause liver toxicity and heart rhythm abnormalities. Linezolid often causes peripheral neuropathy and bone marrow suppression. Moxifloxacin can cause joint pain and tendonitis.

The health department arranged for directly observed therapy (DOT) at the school nurse's office, meaning the girl had to take her medications in front of a nurse every day. That meant her mother had to drive her to school every morning, even on days when the girl felt too sick to attend class. The mother missed 22 days of work over the first two months of treatment, according to the hospital social worker assigned to the case. She worked as a cashier at a discount store and had no paid sick leave. Her wages dropped by roughly $1,200 over that period.

The family had health insurance through the mother's employer, but it did not cover all the ancillary costs. The antiemetics the girl needed for nausea were not on the formulary. The clinic visits for blood tests to monitor liver function required copays. The mother applied for a patient assistance program offered by the drug manufacturer, but the paperwork took six weeks to process. In the meantime, the family fell behind on rent. This financial strain is not unique: a 2023 study in the journal Public Health Reports found that TB patients in the US face median out-of-pocket costs of $1,500 during treatment, and those with drug-resistant TB face costs exceeding $5,000.

What the Youngstown Case Reveals About Preparedness

The Youngstown case is a stress test for the US public health system, and the system did not pass. Only four of the ten clinical laboratories in the region can perform rapid drug susceptibility testing (DST) for TB. The others send samples to the state lab in Columbus, which adds three to five days to the turnaround time. For a disease where every day of delay means potential transmission, that lag matters.

Molecular testing—which can detect resistance genes in hours rather than days—is not routine for pediatric TB in most US hospitals. The girl's initial sputum sample was sent for culture, which took two weeks. The DST results came back three weeks after that. By then, she had been on a standard four-drug regimen for two weeks, which was ineffective against her resistant strain. She may have been infectious during that window.

There is no federal stockpile of pediatric TB drugs. The regimens for children are often formulated as fixed-dose combinations that are not manufactured in the US. The girl's bedaquiline had to be imported from a supplier in Europe under a special FDA waiver. The process took 10 days. During that time, she was on a temporary regimen that was not optimal. A trade-off exists between centralizing drug procurement for efficiency and maintaining local flexibility: centralized systems can negotiate lower prices but may be slower to respond to individual patient needs. The US currently relies on a decentralized system, which contributed to the delay.

Contact investigation reached only 60 percent of the girl's close contacts. The health department said it was short-staffed and that some contacts refused to be tested. Two of the contacts were lost to follow-up after moving out of state. The investigation took 11 weeks to complete, by which point the window for preventive therapy had closed for some contacts. Counter-arguments to increased funding often cite low TB incidence as justification for maintaining current levels. However, the cost of a single drug-resistant TB case—estimated at $150,000 to $500,000 for treatment and contact tracing—far exceeds the cost of preventive measures. A 2022 analysis by the CDC found that every dollar spent on TB prevention saves $3 in future treatment costs.

Closing the Gaps Before the Next Strain Arrives

The Youngstown case is a reminder that TB anywhere is TB everywhere. The Beijing lineage strain that infected one girl in Ohio is the same strain that circulates in prisons in Siberia, in mining towns in South Africa, in megacities in India. It does not respect borders, and it does not wait for funding cycles.

What would it take to close the gaps? First, investment in whole-genome sequencing networks that can link cases across states in real time. The CDC has proposed a national TB surveillance platform, but Congress has not funded it. Second, expansion of Medicaid coverage for TB preventive therapy, which is recommended for close contacts but often not covered. Third, training for school nurses and primary care doctors in TB symptom recognition—especially in areas where TB is rare, because that is where it is most likely to be missed.

Fourth, funding for community health workers who can do contact tracing and support patients through treatment. Studies have shown that community-based DOT improves completion rates and reduces costs compared to clinic-based DOT. Fifth, a renewed political commitment to the WHO's End TB Strategy targets, which include a 90 percent reduction in TB incidence by 2035. The US is not on track to meet those targets.

Dr. Thomas Frieden, former director of the CDC and a prominent TB control advocate, has argued that the US should not neglect TB when domestic burden is low, because drug-resistant TB is a global threat that will eventually cost more if ignored. He points to the example of New York City in the 1990s, where a resurgence of multidrug-resistant TB cost over $1 billion to control. The Youngstown case shows that the cost of inaction is not abstract—it is a 9-year-old girl on a six-month regimen of toxic drugs, her mother losing wages, her school scrambling to test classmates.

There are signs of progress. The CDC recently awarded $15 million in grants to states for TB genomic surveillance. The National Institutes of Health is funding a clinical trial of a shorter regimen for drug-resistant TB in children. But these are pilot projects, not systemic fixes. The infrastructure that caught the Youngstown cluster is fragile, and it depends on the dedication of individual health workers who are overworked and underpaid.

The girl is now in her fourth month of treatment. Her sputum cultures have converted to negative, meaning she is no longer infectious. She has gained back some weight. But she still struggles with nausea and fatigue, and she has missed so much school that she may have to repeat the fourth grade. Her mother is hoping for the best, but she is also worried about what happens when the six-month regimen ends. The girl will need follow-up for at least two years to watch for relapse.

The case has sparked a local conversation about the state of public health in Youngstown. The city council held a hearing in April 2026, and the health department director testified that the department had lost three of its five TB staff positions since 2020. The mayor promised to request additional funding from the state. Whether that funding will materialize is uncertain. In the meantime, the girl's classmates have been tested, and none have active TB. But some are taking preventive therapy, and the health department is watching them closely.

This story is not just about one girl in Ohio. It is about what happens when a disease that is preventable and curable is allowed to slip through the cracks of a fragmented health system. Continued surveillance and investment are essential to prevent further spread.

For more on how TB strains spread across borders, see our report on black market TB drugs in Mumbai and the challenges of delivering care in under-resourced settings.